Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy.

Abstract

Omalizumab added to an optimised therapy significantly improves clinical outcomes in difficult-to-treat, persistent allergic asthma. Costs also increased, but proved justified by health benefits achieved.